Any current/future new fundraising through debt or equity?

The planned Greenfield expansion at Tarapur involves a CAPEX of Rs. 140 crores. Financial closure for Rs. 120 crores is already in place for this project. Funding for this includes approximately Rs. 80 crores through debt and Rs. 40 crores through internal accruals. So far, about Rs. 8 crores have been spent on this project entirely from internal accruals. There is no mention of any new equity fundraising during this period; focus is on debt and internal accruals for funding expansion.

Any current/future capex/capital investment/strategic investment?

Macrotech Brownfield expansion completed last quarter; validation batches ongoing with commercialization expected from the current quarter. Greenfield expansion at Tarapur underway; civil construction started December with work progressing well. Tarapur CAPEX revised to Rs. 140 crores (up from earlier Rs. 100 crores), driven by inflation and higher material costs. Tarapur project will bring 50% capacity addition; expected completion and production start in FY24. Tarapur CAPEX to be funded through a mix of debt and internal accruals. Aim to increase outsource production from current 10% to 15%

Future growth expectations in sales/revenue/volumes?

The poultry product business is expected to grow by 100% to 125% in the current year. Five new molecules in the pipeline are expected to add revenue; two are large volume commodity products with a worldwide market potential of around Rs. 300 crores. Initial sales target for these new products is Rs. 10-15 crores in the first year, aiming for 10%-15% market share over 3 years. The company targets about 20%-25% volume growth annually. Macrotech Brownfield expansion will add Rs. 40-50 crores in sales capacity, expected to contribute from Q2/Q3. Greenfield expansion at Tarapur will add 50% capacit

Future growth expectations in earnings/operating earnings/profits/EPS?

The company aims for about 20-25% volume growth annually in the veterinary API segment. Long-term growth story remains strong despite short-term margin pressures due to raw material cost inflation. New products pipeline includes 5 molecules with more than 5-step synthesis; these are expected to be margin accretive. Greenfield expansion at Tarapur (Rs. 140 crores capex) will add 50% capacity by FY24, expected to contribute positively to sales and margins. Macrotech Brownfield expansion completed; expected to add Rs. 40-50 crores in sales with steady margins, impacting revenues within th

Current/ Expected Orderbook/ Pending Orders?

The next demand for products is expected only in July, as mentioned by Rahul Nachane. Current booking/orders are valid till July, indicating ongoing orders but with limited advance visibility beyond that. There is some resistance in the market currently in accepting price increases, so demand is somewhat muted in the short term. Customers are holding back demand temporarily due to pricing pushback but are expected to return once prices stabilize. No explicit current orderbook value or exact pending order quantity is disclosed. Overall, order intake appears steady with adjustments in timing due

IN US

Sale is live|00:00:00left today

NGL Fine Chem LtdQ1 FY22Pharmaceuticals & Biotechnology

NGL Fine Chem Ltd Q1 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹3,054P/E: 48.8Market Cap: ₹1.5K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→The poultry product business is expected to grow by 100% to 125% in the current year.
→Five new molecules in the pipeline are expected to add revenue; two are large volume commodity products with a worldwide market potential of around Rs. 300 crores.
→Initial sales target for these new products is Rs. 10-15 crores in the first year, aiming for 10%-15% market share over 3 years.
→The company targets about 20%-25% volume growth annually.
→Macrotech Brownfield expansion will add Rs. 40-50 crores in sales capacity, expected to contribute from Q2/Q3.
→Greenfield expansion at Tarapur will add 50% capacity, aiming for appx. Rs. 200 crores in sales on a Rs. 100 crore investment (revised CAPEX now Rs. 140 crores).
→Overall, growth is driven by acquiring more customers, product diversification, and increasing acceptance in the market.

Margin guidance

Category 3

→The company aims for about 20-25% volume growth annually in the veterinary API segment.
→Long-term growth story remains strong despite short-term margin pressures due to raw material cost inflation.
→New products pipeline includes 5 molecules with more than 5-step synthesis; these are expected to be margin accretive.
→Greenfield expansion at Tarapur (Rs. 140 crores capex) will add 50% capacity by FY24, expected to contribute positively to sales and margins.
→Macrotech Brownfield expansion completed; expected to add Rs. 40-50 crores in sales with steady margins, impacting revenues within the current fiscal year.
→Outsourcing increase from 10% to 15% targeted, aiding near-term growth and cost competitiveness.
→Short-term margin challenges expected for 2 more quarters due to elevated input costs and market resistance to price hikes; normalization expected within 6-9 months.
→Sustained market share gains and expanded customer base underpin optimistic future growth outlook.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→The planned Greenfield expansion at Tarapur involves a CAPEX of Rs. 140 crores.
→Financial closure for Rs. 120 crores is already in place for this project.
→Funding for this includes approximately Rs. 80 crores through debt and Rs. 40 crores through internal accruals.
→So far, about Rs. 8 crores have been spent on this project entirely from internal accruals.
→There is no mention of any new equity fundraising during this period; focus is on debt and internal accruals for funding expansion.

Order book

→The next demand for products is expected only in July, as mentioned by Rahul Nachane.
→Current booking/orders are valid till July, indicating ongoing orders but with limited advance visibility beyond that.
→There is some resistance in the market currently in accepting price increases, so demand is somewhat muted in the short term.
→Customers are holding back demand temporarily due to pricing pushback but are expected to return once prices stabilize.
→No explicit current orderbook value or exact pending order quantity is disclosed.
→Overall, order intake appears steady with adjustments in timing due to pricing dynamics and market conditions.

Capex plans

Yes

→Macrotech Brownfield expansion completed last quarter; validation batches ongoing with commercialization expected from the current quarter.
→Greenfield expansion at Tarapur underway; civil construction started December with work progressing well.
→Tarapur CAPEX revised to Rs. 140 crores (up from earlier Rs. 100 crores), driven by inflation and higher material costs.
→Tarapur project will bring 50% capacity addition; expected completion and production start in FY24.
→Tarapur CAPEX to be funded through a mix of debt and internal accruals.
→Aim to increase outsource production from current 10% to 15% by end of FY23 to stay asset-light and support sales growth.
→Continuous debottlenecking and process improvements ongoing for near-term growth.
→Despite inflation and global challenges, company continues to invest strategically to maintain market position and cost competitiveness.

How does NGL Fine Chem Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1NGL Fine Chem Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like NGL Fine Chem Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio